Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.

Frontiers in immunology

Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR.
PMID: 34712243
Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021.

The therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by the development of graft-versus-host disease (GVHD). In GVHD, rigorous pre-conditioning regimen resets the immune landscape and inflammatory milieu causing immune dysregulation, characterized by an expansion of...

Cite
Mohamed FA, Thangavelu G, Rhee SY, et al. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021;12:757836doi: 10.3389/fimmu.2021.757836.
Mohamed, F. A., Thangavelu, G., Rhee, S. Y., Sage, P. T., O'Connor, R. S., Rathmell, J. C., & Blazar, B. R. (2021). Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Frontiers in immunology, 12757836. https://doi.org/10.3389/fimmu.2021.757836
Mohamed, Fathima A, et al. "Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease." Frontiers in immunology vol. 12 (2021): 757836. doi: https://doi.org/10.3389/fimmu.2021.757836
Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021. PMID: 34712243; PMCID: PMC8546182.
Copy Download .nbib Format: NLM
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group.

Blood cancer journal

El Jurdi N, Elhusseini H, Beckman J, DeFor TE, Okoev G, Rogosheske J, Lazaryan A, Weiler K, Bachanova V, Betts BC, Blazar BR, Brunstein CG, He F, Holtan SG, Janakiram M, Gangaraju R, Maakaron J, MacMillan ML, Rashidi A, Warlick ED, Bhatia S, Vercellotti G, Weisdorf DJ, Arora M.
PMID: 34006823
Blood Cancer J. 2021 May 18;11(5):96. doi: 10.1038/s41408-021-00488-2.

Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with systemic inflammation and endothelial dysfunction, increasing risk for thromboembolic events (TEE). In 145 adult recipients who developed cGVHD after a matched sibling or umbilical cord blood...

Cite
El Jurdi N, Elhusseini H, Beckman J, et al. High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer J. 2021;11(5):96doi: 10.1038/s41408-021-00488-2.
El Jurdi, N., Elhusseini, H., Beckman, J., DeFor, T. E., Okoev, G., Rogosheske, J., Lazaryan, A., Weiler, K., Bachanova, V., Betts, B. C., Blazar, B. R., Brunstein, C. G., He, F., Holtan, S. G., Janakiram, M., Gangaraju, R., Maakaron, J., MacMillan, M. L., Rashidi, A., Warlick, E. D., Bhatia, S., Vercellotti, G., Weisdorf, D. J., & Arora, M. (2021). High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood cancer journal, 11(5), 96. https://doi.org/10.1038/s41408-021-00488-2
El Jurdi, Najla, et al. "High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group." Blood cancer journal vol. 11,5 (2021): 96. doi: https://doi.org/10.1038/s41408-021-00488-2
El Jurdi N, Elhusseini H, Beckman J, DeFor TE, Okoev G, Rogosheske J, Lazaryan A, Weiler K, Bachanova V, Betts BC, Blazar BR, Brunstein CG, He F, Holtan SG, Janakiram M, Gangaraju R, Maakaron J, MacMillan ML, Rashidi A, Warlick ED, Bhatia S, Vercellotti G, Weisdorf DJ, Arora M. High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer J. 2021 May 18;11(5):96. doi: 10.1038/s41408-021-00488-2. PMID: 34006823; PMCID: PMC8131386.
Copy Download .nbib Format: NLM
Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Frontiers in cell and developmental biology

Nicholls J, Cao B, Le Texier L, Xiong LY, Hunter CR, Llanes G, Aguliar EG, Schroder WA, Phipps S, Lynch JP, Cao H, Heazlewood SY, Williams B, Clouston AD, Nefzger CM, Polo JM, Nilsson SK, Blazar BR, MacDonald KPA.
PMID: 34631716
Front Cell Dev Biol. 2021 Sep 22;9:737880. doi: 10.3389/fcell.2021.737880. eCollection 2021.

Regulatory T cell (Treg) reconstitution is essential for reestablishing tolerance and maintaining homeostasis following stem-cell transplantation. We previously reported that bone marrow (BM) is highly enriched in autophagy-dependent Treg and autophagy disruption leads to a significant Treg loss, particularly...

Cite
Nicholls J, Cao B, Le Texier L, et al. Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Front Cell Dev Biol. 2021;9:737880doi: 10.3389/fcell.2021.737880.
Nicholls, J., Cao, B., Le Texier, L., Xiong, L. Y., Hunter, C. R., Llanes, G., Aguliar, E. G., Schroder, W. A., Phipps, S., Lynch, J. P., Cao, H., Heazlewood, S. Y., Williams, B., Clouston, A. D., Nefzger, C. M., Polo, J. M., Nilsson, S. K., Blazar, B. R., & MacDonald, K. P. A. (2021). Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in cell and developmental biology, 9737880. https://doi.org/10.3389/fcell.2021.737880
Nicholls, Jemma, et al. "Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control." Frontiers in cell and developmental biology vol. 9 (2021): 737880. doi: https://doi.org/10.3389/fcell.2021.737880
Nicholls J, Cao B, Le Texier L, Xiong LY, Hunter CR, Llanes G, Aguliar EG, Schroder WA, Phipps S, Lynch JP, Cao H, Heazlewood SY, Williams B, Clouston AD, Nefzger CM, Polo JM, Nilsson SK, Blazar BR, MacDonald KPA. Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Front Cell Dev Biol. 2021 Sep 22;9:737880. doi: 10.3389/fcell.2021.737880. eCollection 2021. PMID: 34631716; PMCID: PMC8493124.
Copy Download .nbib Format: NLM
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.

Frontiers in immunology

Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR.
PMID: 34712243
Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021.

The therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by the development of graft-versus-host disease (GVHD). In GVHD, rigorous pre-conditioning regimen resets the immune landscape and inflammatory milieu causing immune dysregulation, characterized by an expansion of...

Cite
Mohamed FA, Thangavelu G, Rhee SY, et al. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021;12:757836doi: 10.3389/fimmu.2021.757836.
Mohamed, F. A., Thangavelu, G., Rhee, S. Y., Sage, P. T., O'Connor, R. S., Rathmell, J. C., & Blazar, B. R. (2021). Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Frontiers in immunology, 12757836. https://doi.org/10.3389/fimmu.2021.757836
Mohamed, Fathima A, et al. "Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease." Frontiers in immunology vol. 12 (2021): 757836. doi: https://doi.org/10.3389/fimmu.2021.757836
Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021. PMID: 34712243; PMCID: PMC8546182.
Copy Download .nbib Format: NLM
The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Antin JH.
PMID: 20640174
Biol Blood Marrow Transplant. 2010 Jan 01;16(1):S1. doi: 10.1016/j.bbmt.2009.10.012.

No abstract available.

Cite
Antin JH. The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010;16(1):S1doi: 10.1016/j.bbmt.2009.10.012.
Antin, J. H. (2010). The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 16(1), S1. https://doi.org/10.1016/j.bbmt.2009.10.012
Antin, Joseph H. "The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation vol. 16,1 (2010): S1. doi: https://doi.org/10.1016/j.bbmt.2009.10.012
Antin JH. The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jan 01;16(1):S1. doi: 10.1016/j.bbmt.2009.10.012. PMID: 20640174; PMCID: PMC2904624.
Copy Download .nbib Format: NLM
Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.

JCI insight

Monlish DA, Beezhold KJ, Chiaranunt P, Paz K, Moore NJ, Dobbs AK, Brown RA, Ozolek JA, Blazar BR, Byersdorfer CA.
PMID: 34291733
JCI Insight. 2021 Jul 22;6(14). doi: 10.1172/jci.insight.143811.

Allogeneic hematopoietic stem cell transplantation is a viable treatment for multiple hematologic diseases, but its application is often limited by graft-versus-host disease (GVHD), where donor T cells attack host tissues in the skin, liver, and gastrointestinal tract. Here, we...

Cite
Monlish DA, Beezhold KJ, Chiaranunt P, et al. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. JCI Insight. 2021;6(14)doi: 10.1172/jci.insight.143811.
Monlish, D. A., Beezhold, K. J., Chiaranunt, P., Paz, K., Moore, N. J., Dobbs, A. K., Brown, R. A., Ozolek, J. A., Blazar, B. R., & Byersdorfer, C. A. (2021). Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. JCI insight, 6(14), . https://doi.org/10.1172/jci.insight.143811
Monlish, Darlene A, et al. "Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells." JCI insight vol. 6,14 (2021). doi: https://doi.org/10.1172/jci.insight.143811
Monlish DA, Beezhold KJ, Chiaranunt P, Paz K, Moore NJ, Dobbs AK, Brown RA, Ozolek JA, Blazar BR, Byersdorfer CA. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. JCI Insight. 2021 Jul 22;6(14). doi: 10.1172/jci.insight.143811. PMID: 34291733; PMCID: PMC8410053.
Copy Download .nbib Format: NLM
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.

Frontiers in immunology

Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR.
PMID: 34712243
Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021.

The therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by the development of graft-versus-host disease (GVHD). In GVHD, rigorous pre-conditioning regimen resets the immune landscape and inflammatory milieu causing immune dysregulation, characterized by an expansion of...

Cite
Mohamed FA, Thangavelu G, Rhee SY, et al. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021;12:757836doi: 10.3389/fimmu.2021.757836.
Mohamed, F. A., Thangavelu, G., Rhee, S. Y., Sage, P. T., O'Connor, R. S., Rathmell, J. C., & Blazar, B. R. (2021). Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Frontiers in immunology, 12757836. https://doi.org/10.3389/fimmu.2021.757836
Mohamed, Fathima A, et al. "Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease." Frontiers in immunology vol. 12 (2021): 757836. doi: https://doi.org/10.3389/fimmu.2021.757836
Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021. PMID: 34712243; PMCID: PMC8546182.
Copy Download .nbib Format: NLM
Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Frontiers in cell and developmental biology

Nicholls J, Cao B, Le Texier L, Xiong LY, Hunter CR, Llanes G, Aguliar EG, Schroder WA, Phipps S, Lynch JP, Cao H, Heazlewood SY, Williams B, Clouston AD, Nefzger CM, Polo JM, Nilsson SK, Blazar BR, MacDonald KPA.
PMID: 34631716
Front Cell Dev Biol. 2021 Sep 22;9:737880. doi: 10.3389/fcell.2021.737880. eCollection 2021.

Regulatory T cell (Treg) reconstitution is essential for reestablishing tolerance and maintaining homeostasis following stem-cell transplantation. We previously reported that bone marrow (BM) is highly enriched in autophagy-dependent Treg and autophagy disruption leads to a significant Treg loss, particularly...

Cite
Nicholls J, Cao B, Le Texier L, et al. Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Front Cell Dev Biol. 2021;9:737880doi: 10.3389/fcell.2021.737880.
Nicholls, J., Cao, B., Le Texier, L., Xiong, L. Y., Hunter, C. R., Llanes, G., Aguliar, E. G., Schroder, W. A., Phipps, S., Lynch, J. P., Cao, H., Heazlewood, S. Y., Williams, B., Clouston, A. D., Nefzger, C. M., Polo, J. M., Nilsson, S. K., Blazar, B. R., & MacDonald, K. P. A. (2021). Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Frontiers in cell and developmental biology, 9737880. https://doi.org/10.3389/fcell.2021.737880
Nicholls, Jemma, et al. "Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control." Frontiers in cell and developmental biology vol. 9 (2021): 737880. doi: https://doi.org/10.3389/fcell.2021.737880
Nicholls J, Cao B, Le Texier L, Xiong LY, Hunter CR, Llanes G, Aguliar EG, Schroder WA, Phipps S, Lynch JP, Cao H, Heazlewood SY, Williams B, Clouston AD, Nefzger CM, Polo JM, Nilsson SK, Blazar BR, MacDonald KPA. Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control. Front Cell Dev Biol. 2021 Sep 22;9:737880. doi: 10.3389/fcell.2021.737880. eCollection 2021. PMID: 34631716; PMCID: PMC8493124.
Copy Download .nbib Format: NLM
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.

Frontiers in immunology

Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR.
PMID: 34712243
Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021.

The therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by the development of graft-versus-host disease (GVHD). In GVHD, rigorous pre-conditioning regimen resets the immune landscape and inflammatory milieu causing immune dysregulation, characterized by an expansion of...

Cite
Mohamed FA, Thangavelu G, Rhee SY, et al. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021;12:757836doi: 10.3389/fimmu.2021.757836.
Mohamed, F. A., Thangavelu, G., Rhee, S. Y., Sage, P. T., O'Connor, R. S., Rathmell, J. C., & Blazar, B. R. (2021). Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Frontiers in immunology, 12757836. https://doi.org/10.3389/fimmu.2021.757836
Mohamed, Fathima A, et al. "Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease." Frontiers in immunology vol. 12 (2021): 757836. doi: https://doi.org/10.3389/fimmu.2021.757836
Mohamed FA, Thangavelu G, Rhee SY, Sage PT, O'Connor RS, Rathmell JC, Blazar BR. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021 Oct 12;12:757836. doi: 10.3389/fimmu.2021.757836. eCollection 2021. PMID: 34712243; PMCID: PMC8546182.
Copy Download .nbib Format: NLM
An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.

JCI insight

Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR.
PMID: 28614794
JCI Insight. 2017 Jun 15;2(12). doi: 10.1172/jci.insight.92111. eCollection 2017 Jun 15.

Chronic graft-versus-host disease (cGvHD) remains a major complication of allogeneic stem cell transplantation requiring novel therapies. CD146 and CCR5 are expressed by activated T cells and associated with increased T cell migration capacity and Th17 polarization. We performed a...

Cite
Forcade E, Paz K, Flynn R, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017;2(12)doi: 10.1172/jci.insight.92111.
Forcade, E., Paz, K., Flynn, R., Griesenauer, B., Amet, T., Li, W., Liu, L., Bakoyannis, G., Jiang, D., Chu, H. W., Lobera, M., Yang, J., Wilkes, D. S., Du, J., Gartlan, K., Hill, G. R., MacDonald, K. P., Espada, E. L., Blanco, P., Serody, J. S., Koreth, J., Cutler, C. S., Antin, J. H., Soiffer, R. J., Ritz, J., Paczesny, S., & Blazar, B. R. (2017). An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI insight, 2(12), . https://doi.org/10.1172/jci.insight.92111
Forcade, Edouard, et al. "An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition." JCI insight vol. 2,12 (2017). doi: https://doi.org/10.1172/jci.insight.92111
Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15;2(12). doi: 10.1172/jci.insight.92111. eCollection 2017 Jun 15. PMID: 28614794; PMCID: PMC5470889.
Copy Download .nbib Format: NLM
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.

Blood advances

Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ.
PMID: 29296875
Blood Adv. 2017 Nov 14;1(24):2269-2279. doi: 10.1182/bloodadvances.2017009084. eCollection 2017 Nov 14.

We report a clinical trial testing vaccination of autologous myeloblasts admixed with granulocyte-macrophage colony-stimulating factor secreting K562 cells after allogeneic hematopoietic stem cell transplantation (HSCT). Patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with ≥5% marrow blasts...

Cite
Ho VT, Kim HT, Bavli N, et al. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017;1(24):2269-2279doi: 10.1182/bloodadvances.2017009084.
Ho, V. T., Kim, H. T., Bavli, N., Mihm, M., Pozdnyakova, O., Piesche, M., Daley, H., Reynolds, C., Souders, N. C., Cutler, C., Koreth, J., Alyea, E. P., Antin, J. H., Ritz, J., Dranoff, G., & Soiffer, R. J. (2017). Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood advances, 1(24), 2269-2279. https://doi.org/10.1182/bloodadvances.2017009084
Ho, Vincent T, et al. "Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT." Blood advances vol. 1,24 (2017): 2269-2279. doi: https://doi.org/10.1182/bloodadvances.2017009084
Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14;1(24):2269-2279. doi: 10.1182/bloodadvances.2017009084. eCollection 2017 Nov 14. PMID: 29296875; PMCID: PMC5737123.
Copy Download .nbib Format: NLM
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Science advances

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.
PMID: 26601142
Sci Adv. 2015 Nov 06;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

The tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intratumoral immune suppression driven by a specialized form of regulatory T cell (Treg) activation dependent on the PTEN (phosphatase and tensin homolog) lipid phosphatase. PTEN acted...

Cite
Sharma MD, Shinde R, McGaha TL, et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv. 2015;1(10):e1500845doi: 10.1126/sciadv.1500845.
Sharma, M. D., Shinde, R., McGaha, T. L., Huang, L., Holmgaard, R. B., Wolchok, J. D., Mautino, M. R., Celis, E., Sharpe, A. H., Francisco, L. M., Powell, J. D., Yagita, H., Mellor, A. L., Blazar, B. R., & Munn, D. H. (2015). The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Science advances, 1(10), e1500845. https://doi.org/10.1126/sciadv.1500845
Sharma, Madhav D, et al. "The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment." Science advances vol. 1,10 (2015): e1500845. doi: https://doi.org/10.1126/sciadv.1500845
Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv. 2015 Nov 06;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov. PMID: 26601142; PMCID: PMC4640592.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries